Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.88 +0.29 (+1.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics ↗

January 10, 2024

Via Benzinga

Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday? ↗

January 09, 2024

Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...

Via Benzinga

Topics Economy

Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year ↗

January 09, 2024

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product

Via Benzinga

Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match ↗

January 09, 2024

Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.

Via InvestorPlace

The Latest Analyst Ratings for Sarepta Therapeutics ↗

December 12, 2023

Via Benzinga

Could Sarepta Therapeutics Stock Help You Become a Millionaire? ↗

December 09, 2023

Can this struggling stock turn its fortunes around?

Via The Motley Fool

Analyst Ratings for Sarepta Therapeutics ↗

November 21, 2023

Via Benzinga

1 Gene Therapy Stock to Buy and Hold for the Long Haul ↗

November 08, 2023

The biotech has what it takes to overcome recent obstacles.

Via The Motley Fool

Why Is Sarepta Therapeutics (SRPT) Stock Up Today? ↗

January 09, 2024

Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.

Via InvestorPlace

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday ↗

January 09, 2024

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

Via Benzinga

Topics Stocks

2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗

January 09, 2024

Last year wasn't great for either stock, but that's no reason to ignore them.

Via The Motley Fool

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

November 02, 2023

Via Benzinga

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

3 Things About Sarepta Therapeutics Every Smart Investor Knows ↗

December 28, 2023

Mastering this stock requires appreciating a few scientific nuances.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

December 27, 2023

Via Benzinga

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond ↗

December 17, 2023

Many investors are bailing out, but that might be a mistake.

Via The Motley Fool

My Take: 4 Strong Growth Stocks to Buy This Week ↗

December 08, 2023

These strong stocks are still available at a great price. That may not be the case a whole lot longer.

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Via The Motley Fool

3 Stocks You’ll Regret Not Buying Soon: November 2023 ↗

November 16, 2023

These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.

Via InvestorPlace

Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy ↗

November 15, 2023

Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the

Via Benzinga

Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There' ↗

November 15, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.

Via Benzinga

Topics Artificial Intelligence

Is Sarepta Therapeutics Stock a Bad-News Buy? ↗

November 09, 2023

Analysts still expect some sizable returns from the stock.

Via The Motley Fool

Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks? ↗

November 08, 2023

Just because a stock is "on sale" doesn't inherently make it worth purchasing.

Via The Motley Fool

8 Health Care Stocks Whale Activity In Today's Session ↗

November 07, 2023

Via Benzinga

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

SRPT earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 1, 2023 ↗

November 01, 2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today